Image credit: Canva
Prostate cancer is often treated with radiation and ADT (androgen deprivation therapy), but up to 30% of these cancers recur within five years of treatment. A clinical trial led by Ravi A. Madan, M.D., Senior Clinician in the Genitourinary Malignancies Branch, is researching a drug therapy for the disease. The researchers are also seeking to understand if the drug (M9241) will affect the immune system. The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact Amy Hankin at (240) 858-3149 or amy.hankin@nih.gov
Clinicaltrials.gov identifier: NCT05361798
NCI Protocol ID: NCI000114
Official Title: A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
